Reduced expression of Raf-1 kinase inhibitory protein predicts regional lymph node metastasis and shorter survival in esophageal squamous cell carcinoma

Pathology Research and Practice

Volumn 208, Issue 5, 2012, Pages 292-299

  Kim, Hyun Soo ^a   Won, Kyu Yeoun ^b   Kim, Gou Young ^b   Kim, Soo Cheol ^b   Park, Yong Koo ^b   Kim, Youn Wha ^b  

^a Republic of Korea Air Force   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

Author keywords

Esophageal squamous cell carcinoma; Immunohistochemistry; Lymph node; Metastasis; Raf kinase inhibitory protein

Indexed keywords

RAF PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; DOWN REGULATION; ENZYME REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; POSTOPERATIVE PERIOD; PREDICTION; PRIMARY TUMOR; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SURVIVAL TIME; THORAX CANCER;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; REPUBLIC OF KOREA; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84862799037     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.02.011     Document Type: Article

References (34)

1. Al-Mulla F., Hagan S., Al-Ali W., Jacob S.P., Behbehani A.I., Bitar M.S., Dallol A., Kolch W. Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. J. Clin. Pathol. 2008, 61:524-529.
2. Al-Mulla F., Hagan S., Behbehani A.I., Bitar M.S., George S.S., Going J.J., Garfcia J.J., Scott L., Fyfe N., Murray G.I., Kolch W. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J. Clin. Oncol. 2006, 24:5672-5679.
3. WHO Classification of Tumours of the Digestive System 2010, IARC Press, Lyon. F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (Eds.).
4. Chatterjee D., Sabo E., Tavares R., Resnick M.B. Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin. Cancer Res. 2008, 14:2994-3001.
5. AJCC Cancer Staging Manual 2010, Springer, New York. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, A. Trotti (Eds.).
6. Fu Z., Kitagawa Y., Shen R., Shah R., Mehra R., Rhodes D., Keller P.J., Mizokami A., Dunn R., Chinnaiyan A.M., Yao Z., Keller E.T. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 2006, 66:248-256.
7. Fu Z., Smith P.C., Zhang L., Rubin M.A., Dunn R.L., Yao Z., Keller E.T. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Natl. Cancer Inst. 2003, 95:878-889.
8. Hagan S., Al-Mulla F., Mallon E., Oien K., Ferrier R., Gusterson B., Garcia J.J., Kolch W. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin. Cancer Res. 2005, 11:7392-7397.
9. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., Shimada Y., Ari-i S., Wada H., Fujimoto J., Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999, 18:813-822.
10. Hu C., Zhou L., Zhang J., Huang C., Zhang G. Immunohistochemical detection of raf kinase inhibitor protein in normal cervical tissue and cervical cancer tissue. J. Int. Med. Res. 2011, 39:229-237.
11. Kajanne R., Miettinen P., Mehlem A., Leivonen S.K., Birrer M., Foschi M., Kahari V.M., Leppa S. EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J. Cell. Physiol. 2007, 212:489-497.
12. Kim H.S., Kim G.Y., Lim S.J., Kim Y.W. Expression of Raf-1 kinase inhibitory protein in extrahepatic bile duct carcinoma. Korean J. Pathol. 2010, 44:234-242.
13. Kim H.S., Kim G.Y., Lim S.J., Kim Y.W. Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma. Pathology 2010, 42:655-660.
14. Kim H.S., Kim G.Y., Lim S.J., Kim Y.W. Raf-1 kinase inhibitory protein expression in thyroid carcinomas. Endocr. Pathol. 2010, 21:253-257.
15. Kim H.S., Kim G.Y., Lim S.J., Park Y.K., Kim Y.W. Reduced expression of Raf-1 kinase inhibitory protein is a significant prognostic marker in patients with gallbladder carcinoma. Hum. Pathol. 2010, 41:1609-1616.
16. Klemke R.L., Cai S., Giannini A.L., Gallagher P.J., de Lanerolle P., Cheresh D.A. Regulation of cell motility by mitogen-activated protein kinase. J. Cell Biol. 1997, 137:481-492.
17. Kroslak T., Koch T., Kahl E., Hollt V. Human phosphatidylethanolamine-binding protein facilitates heterotrimeric G protein-dependent signaling. J. Biol. Chem. 2001, 276:39772-39778.
18. Krueger J.S., Keshamouni V.G., Atanaskova N., Reddy K.B. Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion. Oncogene 2001, 20:4209-4218.
19. Kuwano H., Sonoda K., Yasuda M., Sumiyoshi K., Nozoe T., Sugimachi K. Tumor invasion and angiogenesis in early esophageal squamous cell carcinoma. J. Surg. Oncol. 1997, 65:188-193.
20. Li H.Z., Gao Y., Zhao X.L., Liu Y.X., Sun B.C., Yang J., Yao Z. Effects of raf kinase inhibitor protein expression on metastasis and progression of human breast cancer. Mol. Cancer Res. 2009, 7:832-840.
21. Li H.Z., Wang Y., Gao Y., Shao J., Zhao X.L., Deng W.M., Liu Y.X., Yang J., Yao Z. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol. Cancer Res. 2008, 6:917-928.
22. McCawley L.J., Li S., Wattenberg E.V., Hudson L.G. Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J. Biol. Chem. 1999, 274:4347-4353.
23. Minoo P., Zlobec I., Baker K., Tornillo L., Terracciano L., Jass J.R., Lugli A. Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am. J. Clin. Pathol. 2007, 127:820-827.
24. Mori D., Yamasaki F., Shibaki M., Tokunaga O. Lateral peritumoral lymphatic vessel invasion can predict lymph node metastasis in esophageal squamous cell carcinoma. Mod. Pathol. 2007, 20:694-700.
25. Mueller H., Flury N., Eppenberger-Castori S., Kueng W., David F., Eppenberger U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int. J. Cancer 2000, 89:384-388.
26. Rice T.W., Zuccaro G., Adelstein D.J., Rybicki L.A., Blackstone E.H., Goldblum J.R. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann. Thorac. Surg. 1998, 65:787-792.
27. Schuierer M.M., Bataille F., Hagan S., Kolch W., Bosserhoff A.K. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res. 2004, 64:5186-5192.
28. Schuierer M.M., Bataille F., Weiss T.S., Hellerbrand C., Bosserhoff A.K. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol. Rep. 2006, 16:451-456.
29. Tachibana M., Yoshimura H., Kinugasa S., Dhar D.K., Shibakita M., Ohno S., Ueda S., Fujii T., Nagasue N. Clinicopathologic factors correlated with number of metastatic lymph nodes in oesophageal cancer. Dig. Liver Dis. 2001, 33:534-538.
30. Wilson M., Rosato E.L., Chojnacki K.A., Chervoneva I., Kairys J.C., Cohn H.E., Rosato F.E., Berger A.C. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J. Surg. Res. 2008, 146:11-15.
31. Yeung K., Seitz T., Li S., Janosch P., McFerran B., Kaiser C., Fee F., Katsanakis K.D., Rose D.W., Mischak H., Sedivy J.M., Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999, 401:173-177.
32. Yeung K.C., Rose D.W., Dhillon A.S., Yaros D., Gustafsson M., Chatterjee D., McFerran B., Wyche J., Kolch W., Sedivy J.M. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol. Cell. Biol. 2001, 21:7207-7217.
33. Yoshida B.A., Sokoloff M.M., Welch D.R., Rinker-Schaeffer C.W. Metastasis-suppressor genes: a review and perspective on an emerging field. J. Natl. Cancer Inst. 2000, 92:1717-1730.
34. Zhang J., Zhi H., Zhou C., Ding F., Luo A., Zhang X., Sun Y., Wang X., Wu M., Liu Z. Up-regulation of fibronectin in oesophageal squamous cell carcinoma is associated with activation of the ERK pathway. J. Pathol. 2005, 207:402-409.